119-HR-1262 Journalist Public Summary

Headline Summary

Give Kids a Chance Act of 2025: a bipartisan push to get kids with cancer access to modern treatments sooner by requiring more pediatric studies, clarifying orphan‑drug exclusivity, and extending an FDA incentive program; it passed the House and now awaits Senate action. [1]Congress.gov — H.R.1262 — Give Kids a Chance Act of 2025 (Status, actions, cosp…[2]Congress.gov — H.R.1262 — Text as Reported in House (key provisions)

What It Does

In plain terms, the bill tells drugmakers: if your new cancer drug targets the same biology driving a childhood cancer, you must plan studies in kids—sometimes alongside standard treatments—so dosing, safety, and early effectiveness data actually exist for pediatric use. It also lets FDA enforce deadlines when companies fall behind, extends a popular “priority review voucher” incentive for rare pediatric diseases through September 30, 2029, and clarifies that a rare‑disease drug’s seven‑year exclusivity blocks only the same use or indication—not every use across the whole disease. [1]Congress.gov — H.R.1262 — Give Kids a Chance Act of 2025 (Status, actions, cosp…[2]Congress.gov — H.R.1262 — Text as Reported in House (key provisions)

• Molecularly targeted pediatric cancer studies can include combinations with existing standard‑of‑care drugs when appropriate, to mirror real‑world treatment. [2]Congress.gov — H.R.1262 — Text as Reported in House (key provisions)
• FDA can issue noncompliance letters and, if due diligence is lacking, apply penalties for missed pediatric study obligations. [2]Congress.gov — H.R.1262 — Text as Reported in House (key provisions)
• Rare Pediatric Disease Priority Review Voucher program is reauthorized through 9/30/2029 (vouchers that speed FDA review). [2]Congress.gov — H.R.1262 — Text as Reported in House (key provisions)
• Orphan‑drug exclusivity is clarified to the “same approved use or indication,” addressing uncertainty after the Catalyst v. Becerra court ruling. [3]U.S. Food & Drug Administration — FDA overview of Catalyst Pharmaceuticals, Inc…[2]Congress.gov — H.R.1262 — Text as Reported in House (key provisions)
• Other add‑ons include new transparency for certain generic applications, updates to the organ transplant network’s funding mechanics, creation of an FDA office to engage Abraham Accords countries, and a Medicare Improvement Fund increase. [2]Congress.gov — H.R.1262 — Text as Reported in House (key provisions)

Who’s For It

• Broad bipartisan backing in the House: 313 cosponsors; passed under suspension by voice vote on December 1, 2025. Supporters say it closes gaps that keep children waiting years for data adults already have. [1]Congress.gov — H.R.1262 — Give Kids a Chance Act of 2025 (Status, actions, cosp…
• Pediatric and rare‑disease advocates (e.g., Kids v Cancer; American Cancer Society Cancer Action Network) endorse the bill, arguing it will spur child‑focused trials and treatments. [4]Kids v Cancer — Kids v Cancer – announcement supporting the Give Kids a Chance…[5]American Cancer Society Cancer Action Network — ACS CAN – Community Support Let…
• Bipartisan Senate champions (Sens. Michael Bennet and Markwayne Mullin) promoted companion legislation with similar goals around pediatric combinations and voucher renewal. [6]U.S. Senate (Sen. Markwayne Mullin) — Press release: Sens. Mullin and Bennet in…[7]Web search · turn 3 #5

Who’s Against It

There’s no high‑profile, organized campaign against the House bill, but some concerns surface around specific pieces:

• Orphan‑drug exclusivity change: Some in industry warn that narrowing exclusivity to the “same use or indication” could weaken investment incentives or create legal uncertainty—concerns reflected in company risk disclosures following the Catalyst decision and related litigation. [8]SEC EDGAR — Example industry risk disclosure discussing orphan‑drug exclusivity…
• PREA enforcement: Companies that miss pediatric study deadlines could face penalties if FDA finds a lack of due diligence; supporters frame this as accountability, while some manufacturers caution about added compliance risk and timing pressures. [2]Congress.gov — H.R.1262 — Text as Reported in House (key provisions)

What’s Next

As of December 2, 2025, H.R. 1262 has passed the House and is awaiting Senate consideration. Senators Bennet and Mullin have introduced related legislation; if the Senate advances and passes a bill, differences would be reconciled before anything reaches the President. [1]Congress.gov — H.R.1262 — Give Kids a Chance Act of 2025 (Status, actions, cosp…[6]U.S. Senate (Sen. Markwayne Mullin) — Press release: Sens. Mullin and Bennet in…

Tone

Neutral and plain‑spoken: this summary avoids insider jargon and lays out what the bill does, why it matters, who’s for or against it, and the next steps—so a typical voter can quickly grasp the stakes.